Hangzhou, China · Founded 2016 · Privately Held (backing)
Developer of biotechnology therapies specializing in autoimmune diseases, immuno-oncology, and metabolic disorders. TJ Biopharma is based in Hangzhou, China and was founded in 2016. Its last reported valuation was $459 million in Sep 2025. It has raised $84.2 million.
Last reported valuation
$459.2M
Oct 2026
Priced at
—
Total raised
$84.2M
Last round
—
Cap table — not yet on record
TJ Biopharma's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of TJ Biopharma with a free account
·The complete investor list: 13 names
·Watch TJ Biopharma: the Monday email on marks, rounds and moves
